A risk-benefit assessment of amifostine in cytoprotection.


Recent advances in chemotherapy have focused on the benefit of high dose regimens, increasing the dose intensity of conventional chemotherapy and using intensified chemotherapy with or without autologous bone marrow rescue. Dose intensity usually increases objective response rates of antineoplastic drugs and might, in some circumstances, improves survival… (More)


Cite this paper

@article{Mabro1999ARA, title={A risk-benefit assessment of amifostine in cytoprotection.}, author={May Mabro and Sandrine J. Faivre and Ernest Raymond}, journal={Drug safety}, year={1999}, volume={21 5}, pages={367-87} }